ARAD, Israel, December 5, 2012 /PRNewswire/ --
Andain Inc. (OTCQB: ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields, today discussed its breakthrough miniature fully disposable and programmable insulin pump.
Andain's miniature insulin pump is an ultra slim, small 'Band-Aid' size patch. Gemini is a fully disposable, water proof, fully programmable insulin pump designed to treat Type I and Type II diabetes for a week. The pump holds 6CC of insulin and is 49mm diameter by 7 mm thick 25 in size, making it very comfortable and almost unnoticeable to wear. Moreover, its ultra-low cost makes it an affordable and clinically superior replacement for pen injector products. Smart on-line monitoring provides a real-time alert for occlusions and leakages.
The plugin universal remote-control unit provides the patient, clinic, and doctor dynamic control and on-going monitoring of the patient's insulin treatment program. As a stand-alone, the pump is pre-programmed for patient treatments, providing tailored-made safe basal Insulin treatment and allows for the program-controlled delivery of manual bolus insulin dosages. A fail-safe mechanism prevents the administration of multiple bolus insulin dosages and fully controls basal insulin to prevent hypo-glycemia.
Andain President and CEO Sam Elimelech, commented, "Our incubator development infrastructure and expert scientific team, combined with our on-board industry experience, allows us the ability to quickly commercialize these promising and superior miniaturizing technologies such as those implemented in our insulin pump product. These are key differentiators that set us apart from our competitors and will fuel our growth moving forward. We look forward to moving these technologies closer to commercialization and delivering new game-changing products to the market."
ABOUT ANDAIN INC
Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain (OTC: ANDN) commercializes novel technologies in the biotech, medical and life sciences fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value. For more information, please visit our website at http://www.andaininc.com.
FORWARD LOOKING STATEMENTS
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Form 10-K filing and other filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov/). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
SOURCE Andain Inc